| Ytd | -66.27% | |
| 1y | -90.33% |
| Open | 0.85 | Prev Close | 0.90 | Low | 0.84 | High | 1.09 | Mkt Cap | 16.01M |
| Vol | 4.80M | Avg Vol | 2.51M | EPS | -3.68 | P/E | N/A | Forward P/E | -0.61 |
| Beta | -2.78 | Short Ratio | 0.39 | Inst. Own | 23.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 0.99 | 200-d Avg | 1.85 | 1yr Est | 18.75 |
TPST News
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular ses
Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regula
Shares of Tempest Therapeutics Inc (NASDAQ: TPST) are trading sharply higher Wednesday morning as in
Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market ses
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the Califo
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks poste
Tempest Therapeutics shares soared 66.53% after hours Tuesday following an exclusive option agreemen
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's a
-Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery p
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-
Tempest Therapeutics, Inc. (Nasdaq: TPST) (the "Company"), a clinical-stage biotechnology co
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tem
On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the "Company"), ente
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the a
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T pro
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications di
BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempe
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “C
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the a
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempe
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tem
TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Cente
Adds dedicated business development leadership to support Tempest's strategic priorities Will lead C
ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th,
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the ana
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Mat
Tempest Therapeutics, Inc. (NASDAQ: TPST - Get Free Report) CEO Matthew Angel acquired 231,482 share
Tempest Therapeutics (NASDAQ: TPST - Get Free Report) is projected to announce its Q4 2025 results b
Tempest Therapeutics has entered into definitive agreements for the purchase and sale of an aggregat
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the
Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Tempest Therapeutics (NASDAQ: TPST - Ge
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, de
100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile w